沙库巴曲缬沙坦治疗射血分数保留心衰的收缩压分析
基于PARAGON-HF试验4795例HFpEF患者,分析基线及平均 achieved 收缩压(SBP)与结局的关系。发现SBP 120-129 mmHg者所有结局风险最低;沙库巴曲缬沙坦较缬沙坦降低SBP 5.2 mmHg,女性降幅更大,但降压效应不能解释其结局获益。
要点
- HFpEF患者基线及平均 achieved SBP 120-129 mmHg与最低风险相关。
- 沙库巴曲缬沙坦较缬沙坦降低SBP 5.2 mmHg,女性降幅大于男性。
- 沙库巴曲缬沙坦的结局获益不受基线SBP影响,且不能由降压效应解释。
核心结论
- HFpEF患者基线及平均 achieved SBP 120-129 mmHg所有结局风险最低。
- 沙库巴曲缬沙坦的治疗效应不受基线SBP影响,其降压效应不能解释结局获益。
研究设计与样本
- 基于PARAGON-HF试验4795例HFpEF参与者,平均年龄73±8岁,52%为女性。
- 分析基线及时间更新平均 achieved SBP四分位(<120、120-129、130-139、≥140 mmHg)与主要结局等的关系。
主要发现
- 多变量调整后,基线及平均 achieved SBP 120-129 mmHg所有结局风险最低。
- 沙库巴曲缬沙坦较缬沙坦4周时降低SBP 5.2 mmHg(95%CI 4.4-6.0),不受基线SBP修饰。
- 沙库巴曲缬沙坦降低SBP女性6.3 mmHg多于男性4.0 mmHg(交互p=0.005)。
- SBP变化与NT-proBNP变化直接相关(p<0.001),与KCCQ-OSS无关(p=0.40)。
- 沙库巴曲缬沙坦与主要结局的关联不受基线SBP修饰(交互p=0.50),调整时间更新SBP后相似。
关键数值与推荐
- 指南推荐HFpEF目标SBP<130 mmHg,但数据有限。
- SBP四分位分组:<120、120-129、130-139、≥140 mmHg。
临床怎么用
- HFpEF患者可考虑将SBP控制在120-129 mmHg以降低风险。
- 沙库巴曲缬沙坦的获益不依赖于基线SBP或降压幅度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines recommend targeting systolic blood pressure (SBP) <130 mm Hg in heart failure with preserved ejection fraction (HFpEF) with limited data. OBJECTIVES: This study sought to determine the optimal achieved SBP and whether the treatment effects of sacubitril/valsartan on outcomes are related to BP lowering, particularly among women who derive greater benefit from sacubitril/valsartan. METHODS: Using 4,795 trial participants, this study related baseline and time-updated mean achieved SBP quartiles (<120, 120 to 129, 130 to 139, ≥140 mm Hg) to the primary outcome (cardiovascular death and total heart failure hospitalization), its components, myocardial infarction or stroke, and a renal composite outcome. At the 16-week visit, the study assessed the relationship between SBP change and Kansas City Cardiomyopathy Questionnaire overall summary score (KCCQ-OSS) and N-terminal pro-B-type natriuretic peptide (NT-proBNP). The study analyzed whether the BP-lowering effects of sacubitril/valsartan accounted for its treatment effects. RESULTS: Average age was 73 ± 8 years, and 52% of participants were women. After multivariable adjustment, baseline and mean achieved SBP of 120 to 129 mm Hg demonstrated the lowest risk for all outcomes. Sacubitril/valsartan reduced SBP by 5.2 mm Hg (95% confidence interval: 4.4 to 6.0) compared with valsartan at 4 weeks, which was not modified by baseline SBP. However, sacubitril/valsartan reduced SBP more in women (6.3 mm Hg) than men (4.0 mm Hg) (interaction p = 0.005). Change in SBP was directly associated with change in NT-proBNP (p < 0.001) but not KCCQ-OSS (p = 0.40). The association between sacubitril/valsartan and the primary outcome was not modified by baseline SBP (interaction p = 0.50) and was similar when adjusting for time-updated SBP, regardless of sex. CONCLUSIONS: Baseline and mean achieved SBP of 120 to 129 mm Hg identified the lowest risk patients with HFpEF. Baseline SBP did not modify the treatment effect of sacubitril/valsartan, and the BP-lowering effects of sacubitril/valsartan did not account for its effects on outcomes, regardless of sex. (Prospective Comparison of ARNI With ARB Global Outcomes in HF With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).
引用
- Selvaraj S, Claggett BL, Böhm M, et al. Systolic Blood Pressure in Heart Failure With Preserved Ejection Fraction Treated With Sacubitril/Valsartan. J Am Coll Cardiol. 2020. PMID: 32192799. doi:10.1016/j.jacc.2020.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。